Silence Therapeutics PLC (SLN) Price to Earnings Multiple

Symbol and logo of brand Silence Therapeutics Corp (SLN)

Silence Therapeutics (SLN) develops cutting-edge RNA therapeutics leveraging a scalable platform that ensures low costs for mass production following certification. Its research centers are based in the UK and Germany, while substance production is distributed across Western contract manufacturing organizations. The asset's market dynamics on GURU.Markets, where the multiple stands at -23.50, confirm its status as a defensive asset independent of global economic cycles.

P/E Multiple: Silence Therapeutics Inc. (SLN) for 09/25/2023 - 11/15/2026

Analytical breakdowns for Silence Therapeutics Inc. (SLN)

- market price and analyst price targets:
Summary company analysis:Silence Therapeutics plc - SLN
Flagship merchandise of Silence Therapeutics PLC

Silence Therapeutics focuses on developing RNA-based drugs to combat hypertension, monetizing its research through partner licensing payments. The P/E ratio reflects the market value of a single unit of the issuer's net profit. The multiplier's dynamics depend directly on price fluctuations and the efficiency of operating expense management. This indicator allows investors to assess the premium paid for the asset relative to its current ability to generate income.

Key competitors

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|NTLA (Intellia) - Company Value to Net Income|Price to Earnings Ratio Stoke STOK|BioLife (BLFS) - Market Cap to Earnings|wavelifesciences.com - P/E Multiple|Market Cap to Net Income MAZE|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio TSHA|QURE - Market Cap to Net Income Ratio|P/E Multiple MGTX|Business Payback Period regenxbio.com|P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Earnings Multiple|PACB - Price to Earnings Ratio|Benitec (BNTC) - Price to Earnings Ratio|DSGN: P/E Multiple|RCKT: Market Price to Net Income Ratio|FDMT (4D Molecular Therapeutics, Inc.) - P/E Multiple|lexeotx.com (LXEO) - Business Payback Period|P/E Multiple KRRO|Price to Earnings Ratio Editas Medicine, Inc. EDIT|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio